LONDON - Physiomics plc (AIM: PYC), a company specializing in mathematical modelling and data science for therapeutic development, has received regulatory and ethical approval for its PREDICT-ONC project. The trial is set to evaluate the company's software designed to optimize cancer chemotherapy dosing, with a focus on the drug GCSF used to treat neutropenia, a common side effect of chemotherapy.
The PREDICT-ONC study, funded by Innovate UK and The Office for Life Sciences, aims to refine the company's personalised dosing software, which has been developed with grants totaling £355,376. The software's initial application was to aid clinicians in determining the correct dosage of chemotherapy drug docetaxel. Following the PARTNER study completed in January 2023, the software also showed potential in dosing GCSF, which mitigates chemotherapy's impact on white blood cells.
The observational clinical trial will recruit breast cancer patients undergoing standard GCSF treatment at Blackpool Teaching Hospitals NHS Foundation Trust, in partnership with Beyond Blood Diagnostics Limited. The trial's data will be instrumental in further developing the software's predictive capabilities.
Despite a delay from the initially targeted start date in the summer of 2024, Dr. Peter Sargent, CEO of Physiomics, expressed confidence that recruitment for the trial can begin promptly. He anticipates that the delay will have minimal impact on the project's projected completion between October and December 2025.
Physiomics and its partners are preparing to collect trial data which will contribute to the advancement of their Personalised Dosing Software (ETR:SOWGn). This development marks a significant step in the company's efforts to improve treatment outcomes for cancer patients.
The information in this article is based on a press release statement from Physiomics plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.